# A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

> **NCT00364546** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 877 (actual)

## Conditions studied

- Osteoarthritis
- Pain Intensity Assessment
- Arthralgia
- Sciatica
- Low Back Pain

## Interventions

- **DRUG:** CG 5503;tapentadol

## Key facts

- **NCT ID:** NCT00364546
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-06
- **Final completion:** 2007-07
- **Target enrollment:** 877 (ACTUAL)
- **Last updated:** 2011-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364546, "A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00364546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*